Second Quarter Results $0.46 earnings per share on 12 percent revenue growth (3 percent local currency)

2 Forward-Looking Statements/ Risk Factors In order to take advantage of the safe harbor provisions of the private securities litigation reform act of 1995, you should understand that we will be making forward-looking statements in this conference. These statements involve a number of risks and uncertainties, all of which are set forth in detail in our annual report on form 10-K, subsequent quarterly reports on form 10-Q, and our other SEC filings. We assume no obligation to update any forward-looking statement based on new information, future events or any other reason.

3 Q2 Overview n 12% revenue growth over Q2, 2002 n 3% revenue growth in local currency n Earnings $0.46 per share n Biotechnology - customer delays in manufacturing campaigns and plant build-outs n Life sciences - genomics decline n Other bioscience - strength in pharmaceutical consumables n Europe weakest revenue growth geographically

4 Americas 45% Europe 36% Asia/Pacific 19% Q2, 2003 Multinational; consumable strength in three major markets (in local currencies) Biotechnology 34% Life Science 14% Other Bioscience Applications 52% Q2, 2003 Consumables and Services 82% Equipment 18% Q2, 2003

5 Q2 Revenue growth - by geographic region Americas$ 84$ 806%5% Europe766419%(1)% Asia/Pacific363211%5% Total U.S. dollar$196$17612%3% % Growth Local $ in millions Q2, 2003Q2, 2002% Growth Currency

6 Q2 Revenue growth by market Biotechnology $63$63<1% Life Science26262% Other Bioscience99945% Total local currency % Foreign Exchange8(7) Total U.S. dollar$196$17612% $ in millions Q2, 2003Q2, 2002 % Growth

7 Percent of Year’s Sales Quarterly sales pattern (in local currencies) Sales % per Quarter Estimated

8 Biotechnology: quarterly revenue growth and trends (in local currencies) $ millions Quarterly Growth: Q – Q Revenues by Quarter: Q – Q ‘00 ‘01 ‘02 ‘03 ‘00 ‘01 ‘02 ’03

9 We are involved in over 90% of the therapeutic antibodies in clinical trials or approved Over 2000 biologicals in pipeline or launched Pharmaprojects V5, from PJP Publications, NYC & London, July, 2003 Over 350 therapeutic antibodies in pipeline or launched

10 Life science: quarterly revenue growth and trends (in local currencies) $ millions Quarterly Growth: Q – Q Revenues by Quarter: Q – Q ‘00 ‘01 ‘02 ’03

11 Actual Dollars (In millions, except EPS) Growth Sales$ 196.4$ % Gross Profit % % of Sales54.9%57.5% SG&A % % of Sales 31.5%30.8% R&D % % of Sales 7.2%7.7% Restructuring and other charges (0.6) 0.5N/A % of Sales (0.3%) (0.3%) Operating income (1)% % of Sales16.6%18.7% Net income from continuing operations$ 22.3$ EPS - continuing operations$ 0.46$ Q2 Income Statement Quarter ended June 30,

12 Revised guidance for 2003 n Revenue guidance, 2nd Half n 11 to 14% projected growth n 5 to 7% in local currency n Revenue growth by market - local currency n Biotechnology: 9 to 11% n Life Sciences: 3 to 5% n Other Bioscience: 3 to 4% n Gross Margins - averaging 55% n SG&A: averaging 31% n R&D: between 7 and 8% n Contribution: approximately 17% n EPS: $1.90 to $1.95 per share